OFD Life Sciences, a division of Oregon Freeze Dry, has been awarded a patent for its LyoPastille oral delivery platform, an orally dissolving tablet (ODT) technology. The company reports that the platform is designed to produce quick‑dissolve tablets that can improve absorption and bioavailability of delivered ingredients, while also aiming to enhance taste and texture for users.
According to OFD Life Sciences, LyoPastille can stabilize ingredients and preserve their activity, which may enable the oral delivery of vaccines and other pharmacological substances. The company describes the technology as a scalable and cost‑effective alternative to other fast‑dissolve tablet formats, with the potential to support therapies that do not require cold‑chain storage and distribution.
OFD Life Sciences states that the LyoPastille platform is intended for use across multiple sectors, including biopharmaceutical, medical technology, animal health and consumer health markets. The company notes that global markets for consumer health products, animal health and pharmaceuticals represent key areas where demand exists for formats that support stability, ease of use and user adherence.
The patented technology is described as compatible with high‑throughput production and industrial‑scale GMP lyophilization capacity. OFD Life Sciences reports that, when combined, these capabilities are expected to reduce costs and turnaround time compared with traditional orally dissolvable pharmaceutical technologies.